Structure-Activity Studies of 3,9-Diazaspiro[5.5]undecane-Based γ-Aminobutyric Acid Type A Receptor Antagonists with Immunomodulatory Effect

The 3,9-diazaspiro[5.5]undecane-based compounds 2027 and 018 have previously been reported to be potent competitive γ-aminobutyric acid type A receptor (GABAAR) antagonists showing low cellular membrane permeability. Given the emerging peripheral application of GABAAR ligands, we hypothesize 2027 analogs as promising lead structures for peripheral GABAAR inhibition. We herein report a study on the structural determinants of 2027 in order to suggest a potential binding mode as a basis for rational design. The study identified the importance of the spirocyclic benzamide, compensating for the conventional acidic moiety, for GABAAR ligands. The structurally simplified m-methylphenyl analog 1e displayed binding affinity in the high-nanomolar range (Ki = 180 nM) and was superior to 2027 and 018 regarding selectivity for the extrasynaptic α4βδ subtype versus the α1- and α2- containing subtypes. Importantly, 1e was shown to efficiently rescue inhibition of T cell proliferation, providing a platform to explore the immunomodulatory potential for this class of compounds.

GABAA receptor β1 -subunit knock-out mice show increased delta power in NREM sleep and decreased theta power in REM sleep

γ-Aminobutyric acid (GABA) acting through heteropentameric GABA_A receptors plays a pivotal role in the sleep-promoting circuitry. Whereas the role of the different GABA_A receptor α-subunits in sleep regulation and in mediating the effect of benzodiazepines for treatment of insomnia is well-described, the β-subunits are less studied. Here we report the first study characterizing sleep in mice lacking the GABA_A receptor β₁ -subunit (β₁ ^-/- mice). We show that β₁ ^-/- mice have a distinct and abnormal sleep phenotype characterized by increased delta power in non-rapid eye movement (NREM) sleep and decreased theta activity in rapid eye movement (REM) sleep compared to β₁ ^+/+ mice, without any change in the overall sleep-wake architecture. From GABA_A receptor-specific autoradiography, it is further demonstrated that functional β₁ -subunit-containing GABA_A receptors display the highest binding levels in the hippocampus and frontal cortex. In conclusion, this study suggests that the GABA_A receptor β₁ -subunit does not play an important role in sleep initiation or maintenance but instead regulates the power spectrum and especially the expression of theta rhythm. This provides new knowledge on the complex role of GABA_A receptor subunits in sleep regulation. In addition, β₁ ^-/- mice could provide a useful mouse model for future studies of the physiological role of delta and theta rhythms during sleep.

Silencing of spontaneous activity at α4β1/3δ GABAA receptors in hippocampal granule cells reveals different ligand pharmacology

BACKGROUND AND PURPOSE

The δ-subunit-containing GABA_A receptors, α₄ β₁ δ and α₄ β₃ δ, in dentate gyrus granule cells (DGGCs) are known to exhibit both spontaneous channel openings (i.e. constitutive activity) and agonist-induced current. The functional implications of spontaneous gating are unclear. In this study, we tested the hypothesis that constitutively active α₄ β_1/3 δ receptors limit agonist efficacy.

EXPERIMENTAL APPROACH

Whole-cell electrophysiological recordings of adult male rat and mouse hippocampal DGGCs were used to characterize known agonists and antagonists at δ-subunit-containing GABA_A receptors. To separate constitutive and agonist-induced currents, different recording conditions were employed.

KEY RESULTS

Recordings at either 24°C or 34°C, including the PKC autoinhibitory peptide (19-36) intracellularly, removed spontaneous gating by GABA_A receptors. In the absence of spontaneous gating, DGGCs responded to the α₄ β_1/3 δ orthosteric agonist Thio-THIP with a four-fold increased efficacy relative to recording conditions favouring constitutive activity. Surprisingly, the neutral antagonist gabazine was unable to antagonize the current by Thio-THIP. Furthermore, a current was elicited by gabazine alone only when the constitutive current was silenced (EC₅₀ 2.1 μM). The gabazine-induced current was inhibited by picrotoxin, potentiated by DS2, completely absent in δ^-/- mice and reduced in β₁ ^-/- mice, but could not be replicated in human α₄ β_1/3 δ receptors expressed heterologously in HEK cells.

CONCLUSION AND IMPLICATIONS

Kinase activity infers spontaneous gating in α₄ β_1/3 δ receptors in DGGCs. This significantly limits the efficacy of GABA_A agonists and has implications in pathologies involving aberrant excitability caused by phosphorylation (e.g. addiction and epilepsy). In such cases, the efficacy of δ-preferring GABA_A ligands may be reduced.

Discovery of a new class of orthosteric antagonists with nanomolar potency at extrasynaptic GABAA receptors

Brain GABA_Α receptors are ionotropic receptors belonging to the class of Cys-loop receptors and are important drug targets for the treatment of anxiety and sleep disorders. By screening a compound library (2,112 compounds) at recombinant human α₄β₁δ GABA_Α receptors heterologously expressed in a HEK cell line, we identified a scaffold of spirocyclic compounds with nanomolar antagonist activity at GABA_Α receptors. The initial screening hit 2027 (IC₅₀ of 1.03 μM) was used for analogue search resulting in 018 (IC₅₀ of 0.088 μM). 018 was most potent at α_3,4,5-subunit containing receptors, thus showing preference for forebrain-expressed extrasynaptic receptors. Schild analysis of 018 at recombinant human α₄β₁δ receptors and displacement of [³H]muscimol binding in rat cortical homogenate independently confirmed a competitive profile. The antagonist profile of 018 was further validated by whole-cell patch-clamp electrophysiology, where kinetic studies revealed a slow dissociation rate and a shallow hill slope was observed. Membrane permeability studies showed that 2027 and 018 do not cross membranes, thus making the compounds less attractive for studying central GABA_Α receptors effects, but conversely more attractive as tool compounds in relation to emerging peripheral GABA_Α receptor-mediated effects of GABA e.g. in the immune system.

Autoradiographic imaging and quantification of the high-affinity GHB binding sites in rodent brain using 3H-HOCPCA

GHB (γ-hydroxybutyric acid) is a compound endogenous to mammalian brain with high structural resemblance to GABA. GHB possesses nanomolar-micromolar affinity for a unique population of binding sites, but the exact nature of these remains elusive. In this study we utilized the highly selective GHB analogue, 3-hydroxycyclopent-1-enecarboxylic acid (HOCPCA) as a tritiated version (³H-HOCPCA) to radioactively label the specific GHB high-affinity binding site and gain further insight into the density, distribution and developmental profile of this protein. We show that, in low nanomolar concentrations, ³H-HOCPCA displays excellent signal-to-noise ratios using rodent brain autoradiography, which makes it a valuable ligand for anatomical quantification of native GHB binding site levels. Our data confirmed that ³H-HOCPCA labels only the high-affinity specific GHB binding site, found in high density in cortical and hippocampal regions. The experiments revealed markedly stronger binding at pH 6.0 (K_d 73.8 nM) compared to pH 7.4 (K_d 2312 nM), as previously reported for other GHB radioligands but similar B_max values. Using ³H-HOCPCA we analyzed the GHB binding protein profile during mouse brain development. Due to the high sensitivity of this radioligand, we were able to detect low levels of specific binding already at E15 in mouse brain, which increased progressively until adulthood. Collectively, we show that ³H-HOCPCA is a highly sensitive radioligand, offering advantages over the commonly used radioligand ³H-NCS-382, and thus a very suitable in vitro tool for qualitative and quantitative autoradiography of the GHB high-affinity site.